[ad_1]
December 16, 2025
2 min read
Key takeaways:
- –80 mm Hg single-use negative wound pressure therapy had a 63.9 relative reduction in wound dehiscence vs. –125 mm Hg device.
- Lower health care related costs were also found with the –80 mm Hg device.
Results showed patients with orthopedic and cardiovascular wounds had lower health care resource use and likelihood of dehiscence with the use of –80 mm Hg vs. –125 mm Hg single-use negative pressure wound therapy device.
“There is a subset of patients who are suffering from surgical site complications that are preventable. The use of negative pressure in these patients may help to prevent these potentially devastating outcomes from occurring,” Ravi K. Bashyal, MD, orthopedic surgeon at Endeavor Health, told Healio. “But we have to balance clinical benefit along with cost consideration.”
Data were derived from Bashyal RK, et al. J Wound Care. 2025;doi:10.12968/jowc.2024.0339.
Using the Premier PINC AI Healthcare Database, Bashyal and colleagues collected data from 57,181 patients who underwent orthopedic or cardiovascular surgery between January 2017 and June 2022 and received either–80 mm Hg (n = 27,856; PICO, Smith & Nephew) or –125 mm Hg (n = 29,325; Prevena, Solventum) single-use negative pressure wound therapy device to prevent surgical site complications. Researchers measured health care resource use endpoints, including index encounter length of stay and cost at the index encounter and at 30 and 90 days postoperatively, as well as clinical endpoints such as incidence of all surgical site infections, superficial surgical site infections, seroma, dehiscence, hematoma at 30 days postoperatively and deep surgical site infections at 90 days postoperatively.
Ravi K. Bashyal
“When we compared PICO with Prevena, [PICO provided] a 63.9 relative reduction in wound dehiscence, which was statistically significant,” Bashyal said. “There was also 21.95% lower costs at admission, 30 days and 90 days.”
Bashyal said he hopes these results will provide surgeons with an opportunity to critically examine low-pressure and high-pressure single-use negative pressure wound therapy devices and take into consideration how each impact clinical outcomes and costs.
“I hope this study reenergizes physicians to look at their rates of surgical site complication and their rates of surgical site infection to make sure they are doing all they can, especially in their high-risk patients who are more likely to have preventable surgical site complications and surgical site infections and to harness and utilize single-use negative pressure therapy to minimize those rates of complication and minimize those poor outcomes,” Bashyal said.
For more information:
Ravi K. Bashyal, MD, wishes to be contacted through Libi Stein at libi@eatmorefruit.com.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
[ad_2]
Source link
